Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
19/26/19	₩17,180.00	+2.26%	1,21,792
16/26/16	₩16,800.00	+4.87%	2,00,271
15/26/15	₩16,020.00	-9.54%	2,13,731
14/26/14	₩17,710.00	+4.05%	2,71,494
13/26/13	₩17,020.00	-4.49%	2,38,499

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 19/10/2026			5-day change	1st Jan Change
17,180.00 ^KRW	+2.26%		-3.59%	-85.68%

14/10	Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate	CI
23/08	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI

Market Cap	37TCr 28Cr 25Cr 23Cr 21Cr 40Cr 2.66TCr 40Cr 277.96Cr 109.3Cr 1.39TCr 105.3Cr 103.09Cr 4.45TCr	P/E 2024 *	-	P/E 2025	-59.5x
Enterprise Value	27TCr 20Cr 18Cr 17Cr 15Cr 28Cr 1.9TCr 29Cr 198.3Cr 78Cr 992.13Cr 75Cr 74Cr 3.17TCr	EV / Sales 2024 *	-	EV / Sales 2025	1,03,580x
Free-Float	83.68%	Yield 2024 *	-	Yield 2025	-

14/10	Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate	CI
23/08	Orum Therapeutics Receives FDA Clearance Of IND Application For ORM-1153, A Novel CD123-GSPT1 Degrader-Antibody Conjugate	CI
15/07	Alert wrongly tagged to Orum Therapeutics withdrawn	RE
18/04	Orum Therapeutics Presents New Preclinical Data on ORM-1153, A CD123-Targeting Degrader-Antibody Conjugate	CI
13/04	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors	CI
16/01	Orum Therapeutics, Inc. announced that it has received KRW 24.999873175 billion in funding from a group of investors	CI
05/01	Orum Therapeutics Appoints Chad May as Chief Scientific Officer	CI
18/12	Orum Therapeutics, Inc. announced that it expects to receive KRW 24.999873175 billion in funding from a group of investors	CI
04/11	Orum Therapeutics Announces Presentation of Preclinical Data for Orm-1153 At the 2025 American Society of Hematology Annual Meeting	CI
15/25/15	Orum Therapeutics Appoints Dorin Toader as Head of Platform Technology	CI
23/25/23	Orum Therapeutics, Inc.(KOSDAQ:A475830) added to S&P Global BMI Index	CI
07/25/07	Orum Therapeutics, Inc. has completed an IPO in the amount of KRW 50 billion.	CI
16/24/16	Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex Pharmaceuticals for the Use of Orum's TPD2 Technology to Develop Novel Degrader-Antibody Conjugates	CI

23/08	Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate	AQ
19/12	Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases	AQ
15/25/15	Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orums Degrader-Antibody Conjugate Payload Platforms and Expand TPD Therapeutic Applications	AQ

Orum Therapeutics, Inc. Share Price

Stocks

A475830

KR7475830006

Biotechnology & Medical Research

Valuation: Orum Therapeutics, Inc.

Chart: Orum Therapeutics, Inc.

Latest news: Orum Therapeutics, Inc.

Press Releases: Orum Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Orum Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	+2.26%
1 week	-3.59%
Current month	-22.44%
1 month	-54.06%
3 months	-62.16%
6 months	-80.00%
Current year	-85.68%

1 week	15,690	18,410
1 month	15,690	29,050
Current year	15,690	1,46,600
1 year	15,690	1,46,600
3 years	15,690	1,46,600
5 years	15,690	1,46,600
10 years	15,690	1,46,600

Manager	Title	Age	Since
Seung-Ju Lee CEO	Chief Executive Officer	52	17/08/2016
In-Tae Jeong DFI	Director of Finance/CFO	44	23/10/2023
Chad May CTO	Chief Tech/Sci/R&D Officer	-	05/01/2026

Director	Title	Age	Since
Seung-Ju Lee BRD	Director/Board Member	52	17/08/2016
In-Tae Jeong BRD	Director/Board Member	44	23/10/2023
Un-Nam Park BRD	Director/Board Member	55	01/04/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/02/25	Seung-Ju Lee	Free	Founder	33,88,000	-
21/02/25	In-Tae Jeong	Free	Chief Financial Officer	10,000	-
21/02/25	Un-Nam Park	Free	Director	60,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORUM THERAPEUTICS, INC.	+2.26%	-3.59%	-46.56%	-	28Cr
WUXI APPTEC CO., LTD.	+1.52%	-7.19%	+51.66%	+69.99%	6.58TCr
LONZA GROUP AG	+1.52%	+6.83%	+10.77%	+79.30%	5.19TCr
ARGENX SE	+0.30%	-0.46%	+2.53%	+61.89%	5.12TCr
IQVIA HOLDINGS INC.	-0.38%	+1.40%	+29.98%	+42.37%	4.38TCr
BEONE MEDICINES AG	+0.30%	+5.64%	+16.99%	+133.30%	4.21TCr
REVOLUTION MEDICINES, INC.	+2.35%	-6.08%	+236.69%	+528.10%	3.9TCr
CELLTRION, INC.	+2.16%	+9.87%	+18.92%	+59.70%	3.4TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.44%	-2.71%	+38.65%	+8.16%	2.52TCr
GENMAB A/S	+1.60%	+2.21%	+21.34%	+28.00%	2.28TCr
Average	+1.51%	+0.34%	+38.10%	+112.31%	3.76TCr
Weighted average by Cap.	+1.27%	+0.20%	+46.39%	+114.01%

	2024	2025
Net sales	2.09TCr 1.57Cr 1.4Cr 1.3Cr 1.18Cr 2.21Cr 148.85Cr 2.25Cr 16Cr 6.11Cr 78Cr 5.89Cr 5.77Cr 248.69Cr	2.36Cr 17.7T 15.77T 14.61T 13.29T 24.93T 16.78L 25.34T 2L 68.92T 9L 66.39T 65T 28.03L
Net income	-574.01Cr -43.11L -38.43L -35.59L -32.36L -60.73L -41Cr -61.73L -4.27Cr -1.68Cr -21Cr -1.62Cr -1.58Cr -68Cr	-4.2TCr -3.15Cr -2.81Cr -2.6Cr -2.37Cr -4.44Cr -298.82Cr -4.51Cr -31Cr -12Cr -156.18Cr -12Cr -12Cr -499.26Cr
Net Debt	-9.05TCr -6.79Cr -6.06Cr -5.61Cr -5.1Cr -9.57Cr -644.13Cr -9.73Cr -67Cr -26Cr -336.66Cr -25Cr -25Cr -1.08TCr	-11TCr -8.04Cr -7.17Cr -6.64Cr -6.04Cr -11Cr -762.57Cr -12Cr -80Cr -31Cr -398.56Cr -30Cr -30Cr -1.27TCr